Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30

Benzinga · 2d ago
Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.